DarDoc Research

GLP-1 Trial & Approval Tracker

All studies

GLORY-1 trial results

Adults in China with overweight or obesity, without diabetes.

Mazdutide
Phase
Phase 3
Follow-up
32 weeks
Randomised
610
Sponsor
Innovent Biologics
Publication
New England Journal of Medicine · 2025

Double-blind, placebo-controlled. Treatment-policy estimand.

Mean body weight change at 32 weeks
  • Mazdutide 4 mg−10.09%
  • Mazdutide 6 mg−12.55%
  • Placebo+0.45%
Mean body weight change at 32 weeks
Trial armResult
Mazdutide 4 mg−10.09%
Mazdutide 6 mg−12.55%
Placebo+0.45%
Participants with at least 5% weight loss at 32 weeks
Trial armResult
Mazdutide 4 mg73.9%
Mazdutide 6 mg82.0%
Placebo10.5%
Adverse events leading to treatment discontinuation
Trial armResult
Mazdutide 4 mg1.5%
Mazdutide 6 mg0.5%
Placebo1.0%

Safety. Gastrointestinal adverse events were most common and were mostly mild or moderate.

Published paper PubMed abstract NCT05607680